| [1] |
Global Burden of Disease Cancer C, Fitzmaurice C, Allen C, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the global burden of disease study[J]. JAMA Oncol 2017, 3: 524-548.
|
| [2] |
Caraballo Galva LD, Cai L, Shao Y, et al. Engineering T cells for immunotherapy of primary human hepatocellular carcinoma[J]. J Genet Genomics, 2020, 47(1): 1-15.
|
| [3] |
Docta RY, Ferronha T, Sanderson JP, et al. Tuning T-Cell receptor affinity to optimize clinical risk-benefit when targeting alpha-fetoprotein-positive liver cancer[J]. Hepatology, 2019, 69(5): 2061-2075.
|
| [4] |
Zhu W, Peng Y, Wang L, et al. Identification of α-fetoprotein-specific T-cell receptors for hepatocellular carcinoma immuno-therapy[J]. Hepatology, 2018, 68(2): 574-589.
|
| [5] |
Rosati SF, Parkhurst MR, Hong Y, et al. A novel murine T-cell receptor targeting NY-ESO-1[J]. J Immunother, 2014, 37(3): 135-146.
|
| [6] |
Li Y, Moysey R, Molloy PE, et al. Directed evolution of human T-cell receptors with picomolar affinities by phage display[J]. Nat Biotechnol, 2005, 23(3): 349-354.
|
| [7] |
Robbins PF, Li YF, El-Gamil M, et al. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions[J]. J Immunol, 2008, 180(9): 6116-6131.
|
| [8] |
Gehring AJ, Xue SA, Ho ZZ, et al. Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines[J]. J Hepatol, 2011, 55(1): 103-110.
|
| [9] |
Qasim W, Brunetto M, Gehring AJ, et al. Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient[J]. J Hepatol, 2015, 62(2): 486-491.
|
| [10] |
Nakagawa H, Mizukoshi E, Kobayashi E, et al. Association between high-avidity T-cell receptors, induced by α-fetoprotein-derived peptides, and anti-tumor effects in patients with hepatocellular carcinoma[J]. Gastroenterology, 2017, 152(6): 1395-1406. e10.
|
| [11] |
Zhang HH, Mei MH, Fei R, et al. Regulatory T cell depletion enhances tumor specific CD8 T-cell responses, elicited by tumor antigen NY-ESO-1b in hepatocellular carcinoma patients, in vitro[J]. Int J Oncol, 2010, 36(4): 841-848.
|
| [12] |
Dargel C, Bassani-Sternberg M, Hasreiter J, et al. T cells engineered to express a T-cell receptor specific for glypican-3 to recognize and kill hepatoma cells in vitro and in mice[J]. Gastroenterology, 2015, 149(4): 1042-1052.
|
| [13] |
Spear TT, Callender GG, Roszkowski JJ, et al. TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors[J]. Cancer Immunol Immunother, 2016, 65(3): 293-304.
|
| [14] |
Morgan RA, Chinnasamy N, Abate-Daga D, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy[J]. J Immunother, 2013, 36(2): 133-151.
|
| [15] |
Di Stasi A, Tey SK, Dotti G, et al. Inducible apoptosis as a safety switch for adoptive cell therapy[J]. N Engl J Med, 2011, 365(18): 1673-1683.
|
| [16] |
Scholten KB, Kramer D, Kueter EW, et al. Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells[J]. Clin Immunol, 2006, 119(2): 135-145.
|
| [17] |
Okamoto S, Mineno J, Ikeda H, et al. Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR[J]. Cancer Res, 2009, 69(23): 9003-9011.
|
| [18] |
Cohen CJ, Li YF, El-Gamil M, et al. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond[J]. Cancer Res, 2007, 67(8): 3898-3903.
|
| [19] |
Chang HC, Bao Z, Yao Y, et al. A general method for facilitating heterodimeric pairing between two proteins: application to expression of alpha and beta T-cell receptor extracellular segments[J]. Proc Natl Acad Sci U S A, 1994, 91(24): 11408-11412.
|
| [20] |
Jindal A, Thadi A, Shailubhai K. Hepatocellular carcinoma: etiology and current and future drugs[J]. J Clin Exp Hepatol, 2019, 9(2): 221-232.
|
| [21] |
Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation[J]. J Exp Med, 2000, 192(7): 1027-1034.
|
| [22] |
Zhang L, Davies JS, Serna C, et al. Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models[J]. J Immunother Cancer, 2020, 8(1): e000210.
|
| [23] |
Craddock JA, Lu A, Bear A, et al. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b[J]. J Immunother, 2010, 33(8): 780-788.
|
| [24] |
Sadelain M. T-cell engineering for cancer immunotherapy[J]. Cancer J, 2009, 15(6): 451-455.
|
| [25] |
Brentjens RJ, Latouche JB, Santos E, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15[J]. Nat Med, 2003, 9(3): 279-286.
|
| [26] |
Murga-Zamalloa C, Rolland D, Polk A, et al. Colony-stimulating factor 1 receptor (CSF1R) activates AKT/mTOR signaling and promotes T-Cell lymphoma viability[J]. Clin Cancer Res, 2020, 26(3): 690-703.
|